LUCD vs. CTSO, AMIX, NSPR, APYX, DRIO, ICCM, XAIR, DXR, HSAQ, and GBS
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Cytosorbents (CTSO), Autonomix Medical (AMIX), InspireMD (NSPR), Apyx Medical (APYX), DarioHealth (DRIO), IceCure Medical (ICCM), Beyond Air (XAIR), Daxor (DXR), Health Sciences Acquisitions Co. 2 (HSAQ), and GBS (GBS). These companies are all part of the "surgical & medical instruments" industry.
Cytosorbents (NASDAQ:CTSO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.
32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 6.6% of Cytosorbents shares are held by insiders. Comparatively, 4.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Cytosorbents had 3 more articles in the media than Lucid Diagnostics. MarketBeat recorded 6 mentions for Cytosorbents and 3 mentions for Lucid Diagnostics. Cytosorbents' average media sentiment score of 0.30 beat Lucid Diagnostics' score of 0.22 indicating that Lucid Diagnostics is being referred to more favorably in the news media.
Cytosorbents has higher revenue and earnings than Lucid Diagnostics. Cytosorbents is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Cytosorbents received 410 more outperform votes than Lucid Diagnostics when rated by MarketBeat users. Likewise, 79.52% of users gave Cytosorbents an outperform vote while only 59.52% of users gave Lucid Diagnostics an outperform vote.
Cytosorbents has a net margin of -78.43% compared to Cytosorbents' net margin of -2,169.07%. Lucid Diagnostics' return on equity of -120.24% beat Cytosorbents' return on equity.
Cytosorbents has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
Cytosorbents currently has a consensus price target of $2.50, suggesting a potential upside of 168.18%. Lucid Diagnostics has a consensus price target of $2.75, suggesting a potential upside of 166.99%. Given Lucid Diagnostics' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Lucid Diagnostics.
Summary
Cytosorbents beats Lucid Diagnostics on 11 of the 18 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
